Sorrento Therapeutics (SRNE) revealed impressive results from an independent real-world study by INMEGEN (The Institute of National Genomics Medicine, Mexico) for the detection of COVID-19 infections using COVISTIX antigen rapid tests. Shares of the clinical-stage, antibody-centric biopharmaceutical company were up 3.6% in Monday’s pre-market session following the news. (See Sorrento stock charts on TipRanks) The study was aimed at evaluating the performance and validity of the COVISTIX rapid antigen test for the detection of SARS-CoV-2 in an unselected population and making meaningful comparisons with the Panbio rapid antigen test. For COVISTIX, sensitivity and specificity were 81% and 96.
https://www.tipranks.com/news/sorrento-reports-positive-results-for-covistix-covid-19-detection?utm_source=advfn.com&utm_medium=referral
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Sorrento Therapeutics Charts.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Sorrento Therapeutics Charts.